Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5′-diphosphates

Delphine Goubau[#1], **Martin Schlee**[#2], **Safia Deddouche**[1,*], **Andrea J. Pruijssers**[3,4], **Thomas Zillinger**[2], **Marion Goldeck**[2], **Christine Schuberth**[2], **Annemarthe G. Van der Veen**[1], **Tsutomu Fujimura**[5], **Jan Rehwinkel**[1,†], **Jason A. Iskarpatyoti**[3,4], **Winfried Barchet**[2], **Janos Ludwig**[2], **Terence S. Dermody**[3,4,6], **Gunther Hartmann**[2], and **Caetano Reis e Sousa**[1,‡]

[1]Immunobiology Laboratory, Cancer Research UK, London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3LY, UK

[2]Institut für Klinische Chemie und Klinische Pharmakologie, Universitätsklinikum Bonn, Sigmund-Freud-Strasse 25, D-53127 Bonn, Germany

[3]Department of Pediatrics, Vanderbilt University School of Medicine, D7235 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2581, USA

[4]Elizabeth B. Lamb Center for Pediatric Research, Vanderbilt University School of Medicine, D7235 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2581, USA

[5]Instituto de Biología Funcional y Genómica. Consejo Superior de Investigaciones Científicas/ Universidad de Salamanca, Zacarías González 2, 37007, Salamanca, Spain

[6]Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, D7235 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2581, USA

[#] These authors contributed equally to this work.

SUMMARY

Mammalian cells possess mechanisms to detect and defend themselves from invading viruses. In the cytosol, the RIG-I-like receptors (RLRs), RIG-I (retinoic acid-inducible gene I; encoded by *DDX58*) and MDA5 (melanoma differentiation-associated gene 5; encoded by *IFIH1*) sense atypical RNAs associated with virus infection[1,2]. Detection triggers a signalling cascade *via* the adaptor MAVS that culminates in the production of type I interferons (IFN-α/β; hereafter IFN),

key antiviral cytokines. RIG-I and MDA5 are activated by distinct viral RNA structures and much evidence indicates that RIG-I responds to RNAs bearing a triphosphate (ppp) moiety in conjunction with a blunt-ended, base-paired region at the 5′-end (reviewed in [1-3]). Here we show that RIG-I also mediates antiviral responses to RNAs bearing 5′-diphosphates (5′pp). Genomes from mammalian reoviruses with 5′pp termini, 5′pp-RNA isolated from yeast L-A virus, and base-paired 5′pp-RNAs made by *in vitro* transcription or chemical synthesis, all bind to RIG-I and serve as RIG-I agonists. Furthermore, a RIG-I-dependent response to 5′pp-RNA is essential for controlling reovirus infection in cultured cells and in mice. Thus, the minimal determinant for RIG-I recognition is a base-paired RNA with 5′pp. Such RNAs are found in some viruses but not uninfected cells, indicating that recognition of 5′pp-RNA, like that of 5′ppp-RNA, acts as a powerful means of self/non-self discrimination by the innate immune system.

RIG-I contributes to IFN production by cells infected with reovirus or transfected with the double-stranded (ds)RNA segments of the reovirus genome[4-7]. Short stretches of dsRNA have been thought to be responsible[5] but this is hard to reconcile with the fact that RIG-I activation depends on its C-terminal domain (CTD), which caps RNA ends rather than folding over stems[8-11]. The CTD contains a pocket that accommodates 5′ppp-RNA allowing for extensive interactions with the α- and β-phosphates but, interestingly, less so with the γ-phosphate[8,9,11]. Furthermore, an earlier RIG-I CTD structure showed a complex with a 5′ di-rather than tri-phosphate RNA, possibly as a result of 5′ppp-RNA hydrolysis during crystallisation[11]. Notably, all 10 reovirus genome segments display a free 5′pp on the [-] strand as a result of triphosphate processing by a viral phosphohydrolase[12] (also see Supplementary Fig. 1 and Extended Text for Supplementary Fig. 1). We therefore hypothesized that a 5′pp blunt-ended, base-paired RNA such as found in reovirus genomic RNA can bind RIG-I and serve a physiological agonist for antiviral immunity.

First, we assessed the 5′-phosphate-dependence of stimulation by reovirus RNA. RNA extracted from cells infected with reovirus strain type 3 Dearing (reoT3D) or isolated from reoT3D virus particles (viral RNA; vRNA) induced the expression of an IFN-β reporter gene following transfection into HEK293 cells (Fig. 1a, b). Calf intestinal phosphatase (CIP; Fig. 1a, b) treatment substantially reduced the stimulatory activity of reovirus vRNA, like it did of RNA from IAV-infected cells, a known 5′ppp-dependent RIG-I stimulus[13,14]. Similar results were obtained using reovirus strain type 1 Lang (reoT1L) and a distinct 5′-polyphosphatase (Extended data Fig. 1a and Supplementary Fig. 1i). The response to total reovirus vRNA could be recapitulated using purified large (L), medium (M), and small (S) genome segments (Fig. 1c, d and Extended data Fig. 1b) but not short (<20 residues, labeled <S; Fig. 1c) ssRNA oligonucleotides encapsidated within purified virions[12].

The role of RIG-I *versus* MDA5 in responses to reovirus is unclear[4-7]. HEK293 cells used for reporter assays respond strongly to RIG-I agonists but poorly to triggers of MDA5 (data not shown). To dissect pathways involved in 5′pp-RNA recognition, we therefore switched to mouse cells (dendritic cells [DCs] or mouse embryonic fibroblasts [MEFs]) that display sensitivity to agonists of either RLR (Fig. 1e-h). RIG-I- or MDA5-deficient cells showed the expected loss of IFN-response to selective RIG-I or MDA5 agonists (ppp-IVT-RNA[99nts] or Vero-EMCV-RNA, respectively) but retained the capacity to respond to reovirus vRNA

(Fig. 1f, g and data not shown). Abrogation of the response to reovirus vRNA was only observed in MAVS-deficient or RIG-I/MDA5 doubly-deficient MEFs (Fig. 1e, h)[5]. However, compensation in RIG-I-sufficient but MDA5-deficient ($MDA5^{-/-}$) cells was lost upon vRNA treatment with phosphatase, even though the same treatment did not impact $RIG\text{-}I^{-/-}$ cells (Fig. 1f-g). Thus, when RIG-I is the dominant RLR ($MDA5^{-/-}$ mouse cells or HEK293 human cells), responses to reovirus RNA are sensitive to phosphatase treatment. These data indicate that reovirus genome segments can activate both MDA5 and RIG-I irrespective of their length but that 5′-diphosphates on the reovirus genome are required for RIG-I but not MDA5 activation. A role for 5′-diphosphate-moieties in RIG-I activation by viruses was further confirmed using the L-A totivirus, a dsRNA virus commonly found in *Saccharomyces cerevisiae*, that synthesises transcripts with a 5′pp terminus and is thought to harbour a genome with capped or diphosphate 5′-ends[15,16] (Fig 1i-l and Extended Data Fig. 1c and d). Thus, 5′-diphosphate-bearing RNAs of two distinct viral origins act as agonists for RIG-I.

To determine whether RIG-I associates with 5′pp-containing viral RNA in infected cells, nucleic acids were purified from FLAG-tagged RIG-I that was precipitated from cells infected with either reoT1L or reoT3D. In both cases, we recovered stimulatory RNA from anti-FLAG but not from control immunoprecipitations (Fig. 2a and Extended Data Fig. 2). Similar results were obtained when recombinant FLAG-tagged-RIG-I was incubated with total reovirus vRNA, purified S and L segments or with L-A virus genomic and transcript RNA (Fig. 2b and c). In all cases, the stimulatory activity of RNA associated with RIG-I precipitates was lost after treatment with phosphatase (Fig. 2b and c). Thus, RIG-I can directly bind viral RNAs bearing 5′-diphosphates.

Previous data suggested that *in vitro* transcribed (IVT)-RNA with a 5′pp does not serve as a RIG-I agonist[17]. The IVT-RNA in question bore a single guanosine residue at the 5′ end to permit generation of 5′pp when GDP instead of GTP was included in the transcription reaction[17]. However, because transcriptional elongation requires a triphosphate-bearing nucleoside to form the phosphodiester bond, GDP also prevented the generation of the polymerase copy-back IVT base-paired by-products later demonstrated to be required for RIG-I stimulation[18,19]. We therefore re-synthesised the short 5′-diphosphate transcript (5′pp-IVT-RNA^{25nts}) but this time annealed it to complementary (anti-sense [AS]) synthetic RNA to form the requisite base-paired structure (Fig. 3a). As expected[18,19], a control 5′p-IVT-RNA^{25nts} synthesised using GMP was not stimulatory independently of hybridisation to AS RNA (Fig. 3b). In contrast, the positive control 5′ppp-IVT-RNA^{25nts} made with GTP was stimulatory even without AS annealing (Fig. 3b), as a consequence of the aforementioned by-products[18,19]. Most notably, 5′pp-IVT-RNA^{25nts} was also stimulatory but only when annealed to the AS strand (Fig. 3b). Treatment with phosphatase resulted in a complete loss of stimulatory activity (Fig. 3c), demonstrating strict dependence on the 5′-diphosphate-moieties, and the response was MAVS and RIG-I dependent (Fig. 3d and e), as predicted. Stimulatory activity was preserved in gel purified 5′pp-IVT-RNA^{25nts}+AS (data not shown) and the purity of all guanosine batches used to generate the 5′ mono-, di- or tri-phosphate IVT RNAs was verified by liquid-chromatography mass spectrometry (Extended Data Fig. 3a). Further excluding a role for contamination, no stimulatory RNA was

generated even when a 5′p-IVT-RNA reaction was deliberately "spiked" with up to 10% GTP (Extended Data Fig. 3b).

To strengthen these observations, we chemically synthesised a 5′ppp-RNA of 24nts (5′ppp-RNA^{24nts})[20] and subjected half of the sample to enzymatic hydrolysis of the γ-phosphate using the 5′-RNA triphosphatase activity of the vaccinia virus capping enzyme to generate 5′pp-RNA^{24nts}. The purity of both 5′ppp-RNA^{24nts} and 5′pp-RNA^{24nts} was validated (Extended Data Fig. 3c) and the RNAs were annealed to AS RNA (+AS) and assessed for IFN-inducing ability. 5′pp-RNA^{24nts}+AS was clearly stimulatory for both human and mouse cells in a RIG-I-dependent manner (Fig. 3f,g) and only 3-fold less active than the 5′ppp-RNA^{24nts}+AS control (Fig. 3f). Binding assays showed that RIG-I has similar affinity for both RNAs (apparent K_d of 16.7 nM for 5′pp-RNA^{24nts}+AS *versus* 9.4 nM for 5′ppp-RNA^{24nts}+AS) but binds 5′p-RNA^{24nts}+AS much more weakly (Fig. 3h). The latter also failed to induce IFN (Fig. 3f), consistent with reports that ligand binding is necessary but not sufficient for RIG-I activation[10,21]. Altogether, we conclude that, similar to natural 5′pp-containing viral RNA, man-made 5′pp-base-paired RNAs trigger a RIG-I-dependent response.

Lastly, to assess the physiological importance of our findings, we studied the innate immune response to reovirus infection in MDA5- or MAVS-deficient cells and mice. At 48 h post-infection, there was an increase in reoT3D S4 genome segment copy number in DCs incapable of responding to MDA5 or RIG-I agonists (*MAVS*$^{−/−}$) compared with MDA5-deficient cells in which the RIG-I pathway is intact (Fig. 4a and b). As reported for MEFs[6], the control of viral replication correlated with the respective capacity of *MAVS*$^{−/−}$ and *MDA5*$^{−/−}$ DCs to produce IFN following infection (Fig. 4a and b). Importantly, there was little difference between WT and *MDA5*$^{−/−}$ DCs, indicating that RIG-I alone can serve to control reovirus infection in these cells. This conclusion was confirmed using MEFs deficient for either or both RLRs, in which an increase in viral burden was only observed in RIG-I/MDA5-doubly deficient cells (Fig. 4c). Finally, *MDA5*$^{−/−}$ and *MAVS*$^{−/−}$ mice were perorally infected with reovirus. Reovirus replication in the intestine and the mesenteric lymph nodes (MLN) was significantly greater in RIG-I-signaling-incompetent mice (*MAVS*$^{−/−}$) compared with RIG-I-signaling-competent mice (*MDA5*$^{−/−}$; Fig. 4d and e). Taken together, these data demonstrate that RIG-I can control the replication of reovirus, which bears a 5′-diphosphate dsRNA genome.

The detection of virus infection is crucial for the successful initiation of innate and adaptive antiviral responses. Virus recognition can be mediated by RIG-I through the sensing of viral genomes bearing blunt-ended, base-paired termini with 5′-triphosphates[1-3]. Here, we show that a diphosphate at the 5′-end of blunt-ended, base-paired RNA is in fact sufficient to activate RIG-I. These findings provide physiological meaning to recent structural data demonstrating that the RIG-I CTD can accommodate both 5′pp and 5′ppp-RNA[8,9,11]. They also reiterate the importance of end-rather than stem-based recognition of RNA by RIG-I[9,10,22] and thereby raise the possibility that some viral and synthetic 5′ppp-free RIG-I agonists bear a 5′pp-moiety that contributes to activity. In this regard, the commonly used IFN-inducing stimulus polyinosinic:polycytidylic acid (poly[I:C]) is a homopolymer synthesised from inosine and cytidine diphosphate likely to contain a certain proportion of

5′-ends bearing diphosphates (Extended Data Fig. 4a)[23]. We noticed that the stimulatory capacity of some batches of poly(I:C) can be decreased by phosphatase treament, especially when this is coupled with mild RNase treatment to free up strands (Extended Data Fig. 4b-c). A role for 5′-diphosphates in poly(I:C) and reovirus recognition by RIG-I offers an alternative explanation for the observation that short poly(I:C) or short reovirus RNA segments preferentially activate RIG-I *versus* MDA5[5]. Rather than RIG-I and MDA5 detecting different dsRNA lengths, perhaps it is the ratio of 5′pp-ends to stems that dictates which RLR dominates in recognition. Notably, many viruses display 5′ppp-RNAs in infected cells as a result of utilising a primer-independent mechanism for RNA synthesis. However, viruses such as reoviruses and poxviruses[24] encode 5′-RNA triphosphatases that catalyze hydrolysis of the γ-phosphate in viral genomes or primary transcripts to generate 5′pp-RNAs. In contrast, host cytosolic RNAs (mRNA, tRNA, or rRNA) are uniformly devoid of both 5′ppp- and 5′pp-structures[25]. Thus, the capacity of RIG-I to respond to base-paired RNAs with either a 5′ di- or tri-phosphate does not compromise self-nonself discrimination but extends the universe of viruses that can be detected by a single innate immune sensor.

METHODS

Reagents

Poly(dA:dT) (PO833) and ribavirin were purchased from Sigma-Aldrich and used at 500 ng/ml and 400 μM final concentration, respectively. Cyclic diguanosine monophosphate (cyclic-di-GMP) was purchased from BioLog Life Science Institute (Bremen, Germany) and used at a concentration of 1 μg/ml. Recombinant IFN-A/D was purchased from PBL Assay Science (Piscataway, NJ).

For production of recombinant RIG-I used in Fig. 2, the 3xFLAG-human RIG-I DNA sequence[13] was amplified using forward primer 5′-actcgagttatggactacaaagaccatgacgg-3′ and reverse primer 5′-ttgcggccgctcatttggacatttctgctggatcaa-3′ and cloned into the pBacPAK-His3-GST plasmid. Recombinant 3xFLAG-human RIG-I was expressed as a GST-tagged protein in SF9 insect cells using a baculovirus expression system and purified in a single step by affinity chromatography using glutathione-sepharose matrix (GE Healthcare, Little Chalfont, United Kingdom). The protein was eluted by GST tag cleavage using 3C enzymatic digestion. A final polishing step was accomplished using a Superdex 200 10/300 GL column (GE Healthcare). Protein purity was verified by acrylamide gel electrophoresis, and protein yield was quantified using a Nanodrop apparatus (ThermoScientific, Waltham, MA).

Cells

All cells were mycoplasma negative and cultured using tissue-culture treated polystyrene plates (Falcon, Fisher Scientific International Inc., Hampton, NH) in an incubator with 5-10% CO_2 and at 37 °C. HEK293 cells were provided by Dr. Friedemann Weber (Freiburg, Germany). Vero and L929 cells were obtained from Cancer Research UK Cell Services. Dulbecco's Modified Eagle Medium (DMEM) (Gibco®, Life Technologies, Carlsbad, CA) supplemented to contain 10% FCS (Autogen Bioclear UK, Ltd, Mile Elm, United

Kingdom), 100 U/ml penicillin, 100 U/ml streptomycin, and 0.3 μg/ml glutamine was used as growth medium. HEK293 cells stably expressing 3xFLAG-RIG-I have been described[13]. Granulocyte-macrophage colony-stimulating factor (GM-CSF) bone marrow-derived DCs were prepared as described[26]. $MDA5^{-/-}$ and $RIG-I^{-/-}$ and littermate control MEFs were prepared from 12.5-day embryos using standard protocols. RIG-I/MDA5-deficient MEFs were generated by CRISPR-Cas9-mediated genome engineering[27]. A target sequence in the first exon of murine RIG-I (CTACATGAGTTCCTGGCTCG AGG [PAM motif underlined]) was chosen and appropriate oligonucleotides were cloned into the BbsI site of pX458 (pSpCas9(BB)-2A-GFP; obtained from the laboratory of Feng Zhang *via* Addgene (Cambridge, MA; plasmid 48138)) according to the cloning protocol provided by the Zhang lab (www.genome-engineering.org). MDA5-deficient MEFs immortalized with simian virus 40 large T antigen[7] were transfected with the RIG-I targeting pX458 vector using Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions. Twenty-four hours post-transfection, GFP-positive cells were FACS sorted and cultured at limiting dilution to pick individual colonies. The absence of functional RIG-I was verified in several clones by assessing loss of *ifit1* induction by quantitative PCR following transfection of a known RIG-I agonist (ppp-IVT-RNA[99nts]). In experiments in which these RIG-I/MDA5-deficient MEFs were used, the parental immortalized $MDA5^{-/-}$ MEF line was included as control.

Human PBMCs were isolated as described[11] from whole human blood of healthy, voluntary donors by Ficoll-Hypaque density gradient centrifugation (Biochrom Berlin, Germany) and cultured in RPMI 1640 supplemented to contain 10% FCS, 1.5 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin.

Viruses

All infection work was carried out according to the requirements for handling biological agents in Advisory Committee on Dangerous Pathogens hazard groups. Reovirus strains type 1 Lang (T1L) and type 3 Dearing (T3D) were recovered by plasmid-based reverse genetics from cloned T1L and T3D cDNAs, respectively[28]. The reovirus strain T1L used for mass spectrometry analysis was a kind gift from Søren Paludan, Aarhus University, Denmark. For *in vivo* infections, the T3SA+ strain was used as it readily binds to sialic acid and enhances reovirus infection through adhesion to the cell surface[29]. Reovirus T3SA+ was generated by reassortment of reovirus strains T1L and type 3 clone 44-MA[29]. Virions were purified as described[30]. IAV strain A/Puerto Rico/8/1934 H1N1 was provided by Dr. Thomas Muster (University of Vienna, Austria), and EMCV was obtained from Dr. Ian Kerr.

Nucleic acid preparations

Reovirus genomic RNA was extracted from purified viral particles using TRIzol®LS (Life Technologies). L-A virus transcripts were generated by *in vitro* transcription using purified L-A virions as described[15]. Electrophoresis using 0.8% agarose gels in Tris/borate/EDTA buffer (89 mM Tris, 89 mM boric acid, 2 mM EDTA, pH 8.3) was used to separate reovirus L, M, S, and < S segments and L-A virus genomes from transcripts. Bands were visualized following ethidium bromide (Sigma-Aldrich) staining using a UV transilluminator and a

Dimage Xt digital camera (Minolta, Osaka, Japan). The 1Kb Plus DNA ladder from Life Technologies was used as a reference. RNA segments were purified from gels by adding one volume of UltraPure™ phenol (Life Technologies) per volume of gel and precipitated using ethanol. For mass spectrometry analysis, reovirus genome segments were purified by differential LiCl precipitation[31]. Single-stranded RNA was removed by addition of 2M LiCl, incubated overnight at 4°C and centrifugated at 16,000 rcf for 20 minutes. Subsequently, long dsRNA was precipitated by addition of LiCl to 4M final concentration. The final supernatant (4M LiCl), which contains small RNAs, was discarded. Purity and integrity of dsRNA-preparations was assessed using agarose gel electrophoresis followed by ethidium bromide staining.

For the isolation of RNA from reovirus infected cells, one 80% confluent 145 cm^2 plate of L929 cells was infected at an MOI of 1 plaque forming unit (PFU)/cell. Forty-eight hours later, RNA was isolated using TRIzol® (Life Technologies) according to the manufacturer's protocol. A similar protocol was used for the isolation of RNA from IAV or EMCV-infected Vero cells at 24 h post-infection. 800ng/ml of RNA was used for reporter assays.

ppp-IVT-RNA$^{99\text{nts}}$, which corresponds to the first 99 nucleotides of the neomycin-resistance marker, was prepared using *in vitro* transcription as described[13] and used at concentrations of 200-500 ng/ml. ppp-IVT-RNA$^{933\text{nts}}$ corresponds to 933 nucleotides of the Renilla luciferase coding sequence. The double-stranded ppp-IVT-RNA$^{933\text{nts}}$ was generated by annealing sense and anti-sense ppp-IVT-RNA$^{933\text{nts}}$, respectively. To synthesise p-, pp-, and ppp-IVT-RNA$^{25\text{nts}}$, DNA oligonucleotides sense [5′-AAAGGATCCATTTAGGTGACACTATAGACACACACACACACACACTTTCTCG AGAAA-3′] and antisense [5′-TTTCTCGAGAAAGTGTGTGTGTGTGTGTGTGTCTATAGTGTCACCTAAATGGATC CTTT-3′] were annealed and cloned into pcDNA3.1/V5-His-TOPO. The resulting plasmid was digested with XhoI and BglII (New England Biolabs, Ipswich, MA) and gel-purified (QIAquick Gel Extraction kit, QIAGEN). The *in vitro* transcription was carried out overnight at 37°C with Sp6 RNA polymerase (Sp6 MEGAscript kit, Ambion®, Life Technologies) using GMP, GDP, or GTP (purchased from Sigma-Aldrich (St. Louis, MO) and Carbosynth (Compton, United Kingdom). After DNaseT1 treatment (Ambion) and size-exclusion purification (Illustra™ microspin G25 column; GE Healthcare), the RNA was purified using Ultra Pure™ phenol:chloroform:isoamylalcohol (25:24:1) (Life Technologies) and precipitated using ethanol. The purified RNA was annealed to a synthetic anti-sense RNA oligonucleotide (5′-GAAAGUGUGUGUGUGUGUGUGUGUC-3′; Sigma-Aldrich) by heating for 5 min at 65°C, followed by cooling to room temperature before storage at −20°C.

5′ppp-RNA$^{24\text{nts}}$ (GACGCUGACCCUGAAGUUCAUCUU) was synthesised chemically as described[20]. 5′pp-RNA$^{24\text{nts}}$ was generated by incubating 5′ppp-RNA$^{24\text{nts}}$ with vaccinia virus capping enzyme (Epicentre, Illumina, Madison, WI) for 3 h at 37°C in absence of GTP and S-adenosyl methionine, otherwise according to the manufactures protocol. 5′p-RNA$^{24\text{nts}}$ and AS RNA was derived from Biomers, (Ulm, Germany) or Eurogentec, (Seraing, Belgium). Quality control was performed by mass spectrometry as described[11]. MALDI ToF characterization of 5′ppp-RNA$^{24\text{nts}}$ and 5′pp-RNA$^{24\text{nts}}$ was performed and spectra were

measured using a Bruker Biflex III with linear detection mode and a proprietary Sequenom matrix by Metabion/Martinsried (Germany). For stimulation assays, RNAs were annealed with non-modified oligos with complementary sequence.

Enzymatic treatment of RNA

CIP, SAP (New England Biolabs) and RNA 5′-polyphosphatase (Epicenter) were used according to the manufacturer's instructions. For Terminator nuclease (Epicenter) digestion, RNA was denatured for 3 min at 98°C and immediately cooled on ice (melt and snap cool) after which Terminator N buffer and 1μl of Terminator nuclease with or without 0.5μl vaccinia virus capping enzyme were added. The mixture was incubated for 30 min at 30°C and another 30 min at 37°C. With all enzymatic treatments, control reactions omitting enzymes were carried out in parallel. RNA samples were recovered by extraction with phenol:chloroform:isoamylalcohol or TRIzol®. Nucleic acid pellets were resuspended in RNase/DNase free water (Ambion), and concentrations were measured using the Nanodrop (Thermo Scientific). ReoT3D vRNA samples treated with or without Terminator N were spiked with 10 μg of human RNA to ensure efficient precipitation and to quantify precipitation efficiency (qPCR of GAPDH, data not shown). For RNase T2 digestion of reovirus genome, 40 μg of RNA was diluted to 0.3 μg/μl and denatured by heating for 3 min to 90°C. Subsequently, the RNA was incubated with 150U of RNase T2 (MoBiTec GmbH, Göttingen, Germany) in 125 mM NH_4Ac for 4 h at 37°C. To ensure a complete reaction, the digest was then heated for 60 sec at 90°C, another 150 U of RNase T2 were added and incubation was continued for 1 hour at 37°C. Quantitative digestion was verified by agarose gel electrophoresis and the digestion products were analysed by ESI-LC-MS.

Detection of IFN stimulatory activity

The IFN-β luciferase promoter reporter was employed as described[13]. Cells ($1\text{-}2.5 \times 10^5$) were plated in 0.5 ml of antibiotic-free medium and transfected one day later with a mix of 0.125 μg of IFN-β luciferase promoter reporter (F-luc) and 0.025 μg of Renilla luciferase control (R-luc) using Lipofectamine 2000 (Life Technologies). After 8 h, various concentrations of samples (e.g., IVT-RNA) were transfected into cells using Lipofectamine 2000. Luciferase activity was quantified 24 h later using the Dual-Luciferase Reporter Assay System from Promega (Fitchburg, WI). Firefly luciferase activity was normalized to Renilla luciferase, and fold inductions were calculated relative to a control transfection with water only (F-luc/R-luc). 50, 10, 2, and 0.4 ng/ml of L, M, S and < S reovirus segments were used in reporter assays (Fig 1).

For assays using MEFs, 5×10^4 cells/well were plated into wells of 24-well plates and transfected with test or control RNAs using Lipofectamine 2000. After incubation overnight (16 h), murine IFN-α (multiple subtypes) in culture supernatants was quantified by ELISA as described[32], or MEF RNA was extracted. A similar protocol was employed for assays using bone-marrow derived DCs. Where indicated, cells were IFN-pre-treated as a means to upregulate RLR-expression with 500 units/ml of IFN-A/D (PBL Assay Science) for 24 h. DCs were transfected with 200ng/ml of reoT1L or reoT3D vRNA or 100ng/ml of total L-A RNA.

For assay using PBMCs, 4×10^5 cells were cultured in 96-well plates for stimulation experiments. To inhibit TLR7/8 activity, cells were pre-incubated with 2.5μg/ml chloroquine for 30 min before transfection of RNA using Lipofectamine 2000 (Life Technologies). Human IFN-α levels in culture supernatants 20 h post-transfection were determined by ELISA as described[11].

Quantitative PCR for *ifnb1* and *ifit1*

For real-time quantitative (q)PCR of cell-culture samples, total RNA was isolated using the RNeasy Mini kit (Qiagen, Hilden, Germany) combined with QIAshedder (Qiagen) and RNase-free DNaseI treatment (Qiagen). Mouse tissues (intestine and MLN) were first homogenized using stainless steel beads and the TissueLyzer II (Qiagen). RNA was extracted using TRIzol®, treated with DNase I, and purified using the RNeasy Mini kit (Qiagen). To measure *ifnb1* and *ifit1* expression, cDNA was prepared following instructions in the SuperScript II kit (Life Technologies). Real-time PCR reactions were carried out using an ABI 7500 Fast or ViiA™ 7 real-time PCR system with TaqMan universal master mix and the following primers: *ifnb1* (Mm00439546_s1)*, ifit1* (Mm00515153_m1), and *gapdh* (4352932E) (Applied Biosystems®, Life Technologies). Relative expression (RE) was determined using the AB 7500 Real-Time PCR System (Applied Biosystems) and analysed by Comparative CT Method using the SDS v1.3.1 Relative Quantification Software.

Reovirus replication assay and quantitative PCR

For *in vitro* replication assays, 2×10^6 DCs or 3×10^5 MEFs were seeded into wells of 6-well plates (Corning, Corning, NY) and adsorbed in triplicate with reovirus T3D at an MOI of 0.1 PFU/cell for 1 h at room temperature in serum-free medium, washed once with PBS, and incubated in serum-containing medium for various intervals. Twenty-four or forty-eight hours post-infection RNA from each sample was purified as described above and quantified by RT-qPCR using a modification of a previously described protocol[33]. Following *in vitro* and *in vivo* assays, reovirus S4 vRNA was quantified using 1-4 μg of total RNA extract. Forward (S4 83F, 5′-CGCTTTTGAAGGTCGTGTATCA-3′) primer was used for reverse transcription before reverse (S4 153R, 5′-CTGGCTGTGCTGAGATTGTTTT-3′) primer was added for qPCR amplification. The S4-specific fluorogenic probe used was 5′-dFAM-AGCGCGCAAGAGGGATGGGA-BHQ-1-3′ (Biosearch Technologies, Petaluma, CA). After denaturing RNA for 3 min at 95°C, reverse transcription was performed for 15 min at 50 °C and terminated by incubation for 3 min at 95°C. Subsequently, 40 cycles of qPCR were performed (95°C for 15 sec; 60°C for 30 sec). Reovirus S4 copy numbers were calculated relative to a standard curve prepared using 10-fold dilutions of purified reovirus T3D vRNA as template RNA. The final S4 RNA copy number was normalized to the total sample RNA used per reaction. The S4 segment threshold cycle (C_t) value of each sample was also used to determine the relative expression of S4 to that of *gapdh*.

Reovirus strand specific reverse transcription and quantitative PCR

Strand-specific reverse transcription was carried out by mixing reoT3D vRNA with reverse primers ([+] strand-specific reverse transcription) or forward primers ([-] strand-specific

reverse transcription), as indicated below, heating to 98°C and snap-cooling on ice before incubating for 5 min at 60°C. Reverse transcription was performed at 42°C for 30 min (Revert AID, Thermo Scientific). Subsequently, 40 cycles of qPCR were performed (95°C for 15 sec; 60°C for 20 sec; 72°C for 20 sec) using EvaGreen qPCR master mix (Biotium, Hayward, USA). Primers used were:

1A T3D L1 75-5′	CACTGACCAATCGAATGACG
1A′ T3D L1 262-3′	GCACACGGTTTAGAGCATCA
1B T3D L1 3525-5′	TGTGCAATTAGCCAGAGTGG
1B′ T3D L1 3718-3′	TCGCAGTCATTACCATTCCA
2A T3D L2 31-5′	GGTGAGACTTGCAGACTCGTT
2A′ T3D L2 130-3′	CCCCGGATTAGCATCTAGG
2B T3D L2 3780-5′	TGCTACCTCAAGATTGGGATG
2B′ T3D L2 3902-3′	GCTCACGAGGGACAGTGAG
3A T3D L3 31-5′	GAAGACAAAGGGCAAATCCA
3A′ T3D L3 130-3′	GCCAGCCTTATTGTTTTGCTT
3B T3D L3 3741-5′	CGCAGATACAACTGCCTGAA
3B′ T3D L3 3856-3′	TTGGGAGGATGAGGATCAAG
4A T3D M1 16-5′	GGCTTACATCGCAGTTCCTG
4A′ T3D M1 120-3′	GAAACGTCATTCGCGTCAG
4B T3D M1 2178-5′	GAGCTGCATACAGTGCGAGA
4B′ T3D M1 2298-3′	GCGCGTACGTAGTCTTAGCC
5A T3D M2 19-5′	ACTCTGCAAAGATGGGGAAC
5A′ T3D M2 120-3′	CGATGGTACAGCGGTAGATG
5B T3D M2 2089-5′	AATCGTCTAATCGCCGAGTG
5B′ T3D M2 2199-3′	ATTTGCCTGCATCCCTTAAC
6A T3D M3 20-5′	TGGCTTCATTCAAGGGATTC
6A′ T3D M3 138-3′	ATCCACAGACGGAGTGAAGG
6B T3D M3 2129-5′	CAGCTGATGGTGTTGCTGAC
6B′ T3D M3 2228-3′	CGGGAAGGCTTAAGGGATTA
7A T3D S1 18-5′	TCCTCGCCTACGTGAAGAAG
7A′ T3D S1 163-3′	GGGTGATCCGGAGGATAGTA
7B T3D S1 1268-5′	AGCAGTGGCAGGATGGAGTA
7B′ T3D S1 1374-3′	GAAACTACGCGGGTACGAAA
8A T3D S2 53-5′	GGTTTGGTGGTCTGCAAAAT
8A′ T3D S2 178-3′	TAGCTAAACCCCTCCCAAGG
8B T3D S2 1218-5′	GCAATGGGGACGAGGTAATA
8B′ T3D S2 1319-3′	GTCAGTCGTGAGGGGTGTG
9A T3D S3 19-5′	GTCGTCACTATGGCTTCCTCA
9A′ T3D S3 118-3′	AGGACCGCAGCATGACATA
9B T3D S3 1083-5′	TGACGCCAGTGATGCTAGAC
9B′ T3D S3 1186-3′	TCACCCACCACCAAGACAC
10A T3D S4 54-5′	GGTCATCAGGTCGTGGACTT

10A′ T3D S4 153-3′	CTGGCTGTGCTGAGATTGTT
10B T3D S4 1039-5′	CTCCTGCTGCTCTCACAATG
10B′ T3D S4 1148-3′	CTGTGAAGATGGGGGGTGTTT

Mice and *in vivo* infection studies

All mice used in this study were bred in specific pathogen-free (SPF) conditions by the Cancer Research UK - Biological Resources Unit. Experiments were performed in accordance with national and institutional guidelines for animal care and approved by the Institutional Animal Ethics Committee Review Board, Cancer Research UK. Wild-type C57BL/6J mice were purchased from Charles River Laboratories (Wilmington, MA). The C57BL/6 *MAVS*$^{-/-}$ (also known as *Cardif*$^{-/-}$) mice were provided by Dr. Jürg Tschopp (deceased). *RIG-I* (*Ddx58*) B6;129X1(ICR)-Ddx58^{tm1Aki} and *MDA5* (*Ifih1*) B6;129X1-Ifih1^{tm1Aki} mice were obtained from Dr. Shizuo Akira (Japan) and backcrossed once to C57BL/6J mice. For infection studies, 6-8-week-old male or female mice were inoculated perorally with 10^9 PFU of reovirus T3SA+ in 200 μl borate-buffered saline (0.13 M NaCl, 0.25 mM $CaCl_2$, 1.5 mM $MgCl_2 \times 6H_2O$, 20 mM H_3BO_3, and 0.15 mM $Na_2B_4O_7 \times 10H_2O$) containing 5 g/L of gelatine (Sigma-Aldrich). Forty-eight hours post-infection, mice were euthanized, and organs (intestine and MLNs) were harvested and processed. Investigator was blinded when processing and assessing outcome by giving a unique number to each animal, which was independent of genotype. No randomization to experimental groups was required for these studies and minimum sample size of *n*=5 per group was chosen.

RIG-I immunoprecipitation

For immunoprecipitation (IP) studies using stable FLAG-RIG-I clones, one 80% confluent 145 cm^2 plate of HEK293 cells stably expressing FLAG-RIG-I was washed in phosphate-buffered saline (PBS) and infected with reoT1L at an MOI of 100 PFU/cell in FCS-free medium. Cells were incubated for 1 h at 37°C and 10% CO_2 before adding an equivalent volume of medium supplemented to contain 20% FCS. Four hours later, cells were washed with ice-cold PBS and lysed in 4 ml of ice-cold buffer C (0.5% NP40, 20mM Tris-HCl pH 7.5, 150mM NaCl; 2.5mM $MgCl_2$; complete protease inhibitor [Roche Applied Sciences], 0.1 U/ml RNasin [Promega]). Lysates were incubated on ice for 30 min and centrifuged at 20,000 × g for 15 min to remove cell debris. Resulting supernatants were divided equally and incubated with α-FLAG M2 antibody (Sigma-Aldrich) or control mIgG1 (BD Biosciences, Franklin, NJ) for 1.5-2 h at 4°C on a rotating wheel before adding Gamma Bind Plus Sepharose beads (GE Healthcare). Two hours later, beads were collected by centrifugation and washed five times for 2 min with 1-1.5 ml of buffer C. Bead samples were divided for RNA extraction with Ultra Pure™ phenol:chloroform:isoamylalcohol (25:24:1) (Life Technologies) or subjected to immunoblotting. RNA isolated from beads was resuspended in 20μl of RNase-free water and transfected into HEK293 cells expressing the IFN-β reporter. For IP using recombinant RIG-I, 1 μg of purified protein was incubated with different RNA in lysis buffer C for 2 h at 4°C on a rotating shaker. The rest of the IP was performed using the protocol employed for the RIG-I IP from infected cells.

Alpha Screen RIG-I-binding assay

The binding affinity of RNA for (His_6)-FLAG-tagged wild-type RIG-I was determined as described[18] using an amplified luminescent proximity homogenous assay (AlphaScreen; Perkin Elmer, Waltham, MA). Purified (His_6)-FLAG-RIG-I was incubated with increasing concentrations of biotinylated RNA (non-triphosphorylated antisense RNA is 5′biotinylated) for 1 hour at 37°C in buffer (50 mM Tris/pH7.4, 100 mM NaCl, 0.01% Tween20, 0.1% BSA) and subsequently incubated for 30 min at 25°C with (His_6)-FLAG-RIG-I-binding nickel-chelate acceptor beads (Perkin-Elmer) and biotin-RNA-binding streptavidin donor beads (Perkin Elmer).

Liquid chromatography-mass spectrometry (LC-MS) analysis

Samples of GMP, GDP, and GTP were analysed by LC-MS using an Agilent 1100 LC-MSD. Analysis was carried out using a Zorbax Eclipse XDB-C8 Rapid Resolution HT 3.0 × 50 mm 1.8 micron column. Buffer A is 1% acetonitrile and 0.08% trifluoroacetic acid in milliQ water, and Buffer B is 90% acetonitrile and 0.08% trifluoroacetic acid in milliQ water. Flow rate was 0.425 mls/min, and the gradient was 0% – 40% Buffer B over 8 min. The MS was conducted with positive polarity, fragmentor voltage was 170, drying gas flow 12 L/min, drying gas temperature 350°C, and nebuliser pressure 40 psig. Mass spectra were registered in full-scan mode (m/z 200 to 3000 step size 0.15). RNA samples were analysed by electrospray ionization (ESI) -LC-MS performed by Axolabs GmbH (Kulmbach, Germany) using a Dionex Ultimate3000 RS system coupled to a Bruker maXis Q-ToF mass spectrometer. The samples were analysed with an improved version of the protocol established for ribonucleotide digestion analysis[34]. Analysis of 4 pmol and 50 pmol of an equimolar solution of chemically synthesised pp-RNA[24nts] and ppp-RNA[24nts] treated with RNase T2 served as control. Characterisation of reovirus genome RNA was performed with 50 μl (13 μg) of the RNase T2 digest.

Poly(I:C) studies

Poly(I:C) was obtained from Amersham (GE Healthcare Life Sciences) and treated or not with the dsRNA-specific endoribonuclease, RNase III from Ambion (Life Technologies) as specified by the manufacturer. Digestion was performed at room temperature and halted at 1 min or 5 min following enzyme addition using 125 mM EDTA. Poly(I:C) samples were purified using Ultra Pure™ phenol:chloroform:isoamylalcohol (25:24:1) (Life Technologies) and precipitated using ethanol before being treated with CIP and re-purified as done following RNase III treatment. A fraction of the samples were electrophoresed in 0.8% agarose gels and visualized using ethidium bromide, whereas another fraction was transfected into SV40 large T antigen-immortalized $MDA5^{-/-}$ or $RIG^{-/-}$ MEFs. Cells (5 × 10^4) in aliquots of 0.5 ml antibiotic-free medium were placed into wells of 24-well plates and transfected one day later. For the IFN-βluciferase promoter reporter assay, cells were transfected with a mix of 0.3 μg of IFN-βluciferase promoter reporter (F-luc) and 0.05 μg of Renilla luciferase control (R-luc) using Lipofectamine 2000 (Invitrogen). After 8 h, various concentrations of samples were transfected using Lipofectamine 2000. Luciferase activity was quantified 24 h later using the Dual-Luciferase Reporter Assay System from Promega. Firefly luciferase activity was normalized to Renilla luciferase, and fold inductions were

calculated relative to a control transfection using water only (F-luc/R-luc). For RT-qPCR analysis of *ifit1* levels, cells were transfected with various concentrations of samples using Lipofectamine 2000. Samples were harvested 16 h later, and RNA was extracted as described above.

Statistical analysis

Statistical analyses were performed using unpaired, two-tailed, Student's t-tests or two-way ANOVAs. *P* values of less than 0.05 were considered statistically significant.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

REFERENCES

1. Goubau D, Deddouche S, Reis e Sousa C. Cytosolic sensing of viruses. Immunity. 2013; 38:855–869. [PubMed: 23706667]

2. Schlee M. Master sensors of pathogenic RNA – RIG-I like receptors. Immunobiology. 2013; 218:1322–1335. [PubMed: 23896194]

3. Rehwinkel J, Reis e Sousa C. Targeting the viral Achilles' heel: recognition of 5′-triphosphate RNA in innate anti-viral defence. Curr Opin Microbiol. 2013; 16:485–492. [PubMed: 23707340]

4. Holm GH, et al. Retinoic acid-inducible gene-I and interferon-beta promoter stimulator-1 augment proapoptotic responses following mammalian reovirus infection via interferon regulatory factor-3. J Biol Chem. 2007; 282:21953–21961. [PubMed: 17540767]

5. Kato H, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med. 2008; 205:1601–1610. [PubMed: 18591409]

6. Loo Y-M, et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol. 2008; 82:335–345. [PubMed: 17942531]

7. Pichlmair A, et al. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J Virol. 2009; 83:10761–10769. [PubMed: 19656871]

8. Lu C, et al. The Structural Basis of 5′ Triphosphate Double-Stranded RNA Recognition by RIG-I C-Terminal Domain. Structure. 2010; 18:1032–1043. [PubMed: 20637642]

9. Luo D, et al. Structural insights into RNA recognition by RIG-I. Cell. 2011; 147:409–422. [PubMed: 22000018]

10. Jiang F, et al. Structural basis of RNA recognition and activation by innate immune receptor RIG-I. Nature. 2011; 479:423–427. [PubMed: 21947008]

11. Wang Y, et al. Structural and functional insights into 5′-ppp RNA pattern recognition by the innate immune receptor RIG-I. Nat Struct Mol Biol. 2010; 17:781–787. [PubMed: 20581823]

12. Dermody, TS.; Sherry, B.; Parker, JSL.; Knipe, DM.; Howley, PM. Fields Virology. Vol. 2. Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013.

13. Rehwinkel J, et al. RIG-I Detects Viral Genomic RNA during Negative-Strand RNA Virus Infection. Cell. 2010; 140:397–408.

14. Baum A, Sachidanandam R, García-Sastre A. Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci USA. 2010; 107:16303–16308. [PubMed: 20805493]

15. Fujimura T, Esteban R. Yeast double-stranded RNA virus L-A deliberately synthesizes RNA transcripts with 5′-diphosphate. J Biol Chem. 2010; 285:22911–22918.

16. Fujimura T, Esteban R. Cap-snatching mechanism in yeast L-A double-stranded RNA virus. Proc Natl Acad Sci USA. 2011; 108:17667–17671. [PubMed: 21987792]

17. Hornung V, et al. 5′-Triphosphate RNA Is the Ligand for RIG-I. Science. 2006; 314:994–997. [PubMed: 17038590]

18. Schlee M, et al. Recognition of 5′ Triphosphate by RIG-I Helicase Requires Short Blunt Double-Stranded RNA as Contained in Panhandle of Negative-Strand Virus. Immunity. 2009; 31:25–34. [PubMed: 19576794]

19. Schmidt A, et al. 5′-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc Natl Acad Sci USA. 2009; 106:12067–12072. [PubMed: 19574455]

20. Goldeck M, Tuschl T, Hartmann G, Ludwig J. Efficient Solid-Phase Synthesis of pppRNA by Using Product-Specific Labeling. Angew. Chem. Int. Ed. Engl. 2014; 53:4694–4698. [PubMed: 24668741]

21. Vela A, Fedorova O, Ding SC, Pyle AM. The thermodynamic basis for viral RNA detection by the RIG-I innate immune sensor. J Biol Chem. 2012; 287:42564–42573. [PubMed: 23055530]

22. Kohlway A, Luo D, Rawling DC, Ding SC, Pyle AM. Defining the functional determinants for RNA surveillance by RIG-I. EMBO Rep. 2013; 14:772–779. [PubMed: 23897087]

23. Grunberg-Manago M, Oritz PJ, Ochoa S. Enzymatic synthesis of nucleic acidlike polynucleotides. Science. 1955; 122:907–910. [PubMed: 13274047]

24. Decroly E, Ferron F, Lescar J, Canard B. Conventional and unconventional mechanisms for capping viral mRNA. Nat Rev Microbiol. 2011; 10:51–65. [PubMed: 22138959]

25. Gerlier D, Lyles DS. Interplay between innate immunity and negative-strand RNA viruses: towards a rational model. Microbiol Mol Biol Rev. 2011; 75:468–490. [PubMed: 21885681]

26. Inaba K, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992; 176:1693–1702. [PubMed: 1460426]

27. Ran FA, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013; 8:2281–2308. [PubMed: 24157548]

28. Kobayashi T, Ooms LS, Ikizler M, Chappell JD, Dermody TS. An improved reverse genetics system for mammalian orthoreoviruses. Virology. 2010; 398:194–200. [PubMed: 20042210]

29. Barton ES, Connolly JL, Forrest JC, Chappell JD, Dermody TS. Utilization of sialic acid as a coreceptor enhances reovirus attachment by multistep adhesion strengthening. J Biol Chem. 2001; 276:2200–2211. [PubMed: 11054410]

30. Virgin HW, Bassel-Duby R, Fields BN, Tyler KL. Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing). J Virol. 1988; 62:4594–4604. [PubMed: 2460637]

31. Diaz-Ruiz JR, Kaper JM. Isolation of viral double-stranded RNAs using a LiCl fractionation procedure. Prep. Biochem. 1978; 8:1–17. [PubMed: 643823]

32. Diebold SS, et al. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature. 2003; 424:324–328. [PubMed: 12819664]

33. Boehme KW, Frierson JM, Konopka JL, Kobayashi T, Dermody TS. The reovirus sigma1s protein is a determinant of hematogenous but not neural virus dissemination in mice. J Virol. 2011; 85:11781–11790. [PubMed: 21917967]

34. Ablasser A, et al. cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING. Nature. 2013; 498:380–384. [PubMed: 23722158]

35. Bellamy AR, Hole LV, Baguley BC. Isolation of the trinucleotide pppGpCpU from reovirus. Virology. 1970; 42:415–420. [PubMed: 4321301]

36. Chow N-L, Shatkin AJ. Blocked and Unblocked 5′ Termini in Reovirus Genome RNA. J Virol. 1975; 15:1057–1064. [PubMed: 16789145]

37. Banerjee AK, Shatkin AJ. Guanosine-5′-diphosphate at the 5′ termini of reovirus RNA: evidence for a segmented genome within the virion. J Mol Biol. 1971; 61:643–653. [PubMed: 5167308]

**Fig. 1. RNA from reovirus and L-A virus requires 5′-phosphates to induce a RIG-I-dependent response.**

(a-d) RNA samples were tested in an IFN-β promoter reporter assay in HEK293 cells: (a) RNA from reoT3D- or IAV-infected cells +/−CIP, (b) reoT3D vRNA +/−CIP, (c) reoT1L genome segments, and (d) reoT3D segments +/− CIP. For (b) and (d), RNA integrity was verified by gel electrophoresis. **(e)** IFN-α levels from transfected DCs. **(f-h)** IFN-α levels (f) or relative expression (RE) of *ifit1* (g-h) from control (*MDA5*$^{+/−}$), *RIG-I*$^{−/−}$, *MDA5*$^{−/−}$ or *RIG-I/MDA5*$^{−/−}$ MEFs transfected with reo vRNA (f,h) or isolated reoT1L L segments (g)

+/− CIP. Water and ppp-IVT-RNA[99nts] are controls. For (e-h), cells were treated with ribavirin to block virus replication. **(i)** Total L-A RNA (genome and transcript), L-A genomes and L-A transcripts were analysed as in (a). **(j)** Total L-A RNA was analysed as in (e). **(k-l)** Total L-A RNA +/− shrimp alkaline phosphatase (SAP) was analysed as in (a) or transfected into $MDA5^{-/-}$ DCs and analysed as in (g). Water, ppp-IVT-RNA[99nts], poly(dA:dT) and cyclic-di-GMP were included as controls. All experiments were performed at least twice. For PCR and IFN-α data, the mean (±s.d.) of triplicate technical replicates is shown (* = not detected).

Fig. 2. RIG-I associates with 5′-diphosphate-bearing viral RNAs.
(a) Left, Experimental procedure. Right, IFN-β promoter reporter assay of RNA from RIG-I-precipitates. **(b-c)** (b, left) Experimental procedure using the following input RNA: reoT1L or reoT3D vRNA, reoT3D S or L segments, RNA isolated from reoT1L-infected cells, or total L-A RNA. (b, left) IFN-β promoter reporter assay or (b, right) *ifnb1* expression from IFN-pre-treated *MDA5*$^{-/-}$ DCs (c) following transfection of RNA from RIG-I-precipitates treated +/−CIP. For PCR data, the mean (±s.d) of triplicate technical replicates is shown. All experiments were performed at least twice.

Fig. 3. *De novo* generated base-paired 5′-diphosphate RNA triggers RIG-I.
(**a**) Experimental procedure used to generate 5′pp-IVT-RNA^{25nts}. (**b-c**) IFN-β promoter reporter assay of IVT-RNA^{25nts}+/−AS (b) and pp-IVT-RNA^{25nts}+AS +/−CIP (c). (**d-g**) IFN-α levels (d,f,g) or *ifit1* expression (e) from DCs (d) MEFs (e,g) or human PBMCs (f) transfected with indicated RNAs. Water, poly(dA:dT) or cyclic-di-GMP were included as controls (*not detected). For (f), the value obtained for 800ng/ml of [ppp-RNA^{24nts}+AS] was set to 100%. Mean values (+s.d.) from four donors are shown (***P<0.0001). (**h**) AlphaScreen of RIG-I and synthetic RNA ligands (±s.d.). Units are proportional to RIG-I-ligand complex concentration. One experiment of two is shown.

Fig. 4. RIG-I is required for control of reovirus infection.
(a-c) *ifit1* (a) or reovirus gene segment S4 genome expression ([b-c], right panel) and copy number per µg of RNA ([b-c], left panel) in reoT3D infected DCs (a-b) or control (*RIG-I*[+/−]) *MDA5*[−/−], *RIG-I*[−/−], and *MDA5/RIG-I*[−/−] MEFs. Mean of triplicate biological replicates (±s.d.) is shown. Cyclic-di-GMP was included as a control. *******P* ≤0.01 (unpaired *t*-test). **(d-e)** Abundance of reovirus gene segment S4 determined as in (b) from intestine (d) and MLN (e) of mice following peroral infection with reovirus strain T3SA+. Data were pooled from two experiments. Each symbol represents an individual mouse. Line represents the mean of each group. *P<0.03 and **P<0.008 (unpaired *t*-test).